Fertility Testing: The Complete Guide to Understanding Your Reproductive Health

One of the most empowering steps a couple can take is to understand the state of their fertility — not just when problems arise, but proactively, with knowledge and intention. Fertility testing has become more accessible, more sophisticated, and more clinically meaningful than ever before. Whether you've just started trying to conceive or have been trying for some time, a clear understanding of what these tests measure, what they can and cannot tell you, and how to interpret the results is invaluable.

This guide covers the full spectrum of fertility assessments — from basic hormone panels to advanced diagnostics — for both women and men.

When Should You Consider Fertility Testing?

Standard guidelines recommend seeking a fertility evaluation after:

• 12 months of regular, unprotected intercourse if the woman is under 35
• 6 months if the woman is 35–39
• Immediately or after 3 months if the woman is 40 or older

However, evaluation is appropriate sooner if either partner has any of the following risk factors:

• Irregular or absent menstrual cycles
• Known or suspected endometriosis
• Previous pelvic infections (chlamydia, PID)
• Prior pelvic or abdominal surgery
• Known male factor issues (previous semen abnormalities, testicular surgery)
• Recurrent pregnancy loss (2 or more miscarriages)
• Cancer treatment history
• Family history of premature menopause

And for those who simply want to understand their baseline fertility status — even before actively trying — proactive testing is increasingly popular and clinically sensible.

Female Fertility Testing: A Systematic Overview

Ovarian Reserve Testing

Ovarian reserve refers to the quantity (and to some extent quality) of a woman's remaining eggs. It is one of the most important fertility parameters and declines with age.

Anti-Müllerian Hormone (AMH): AMH is produced by small growing follicles in the ovaries and is the most reliable marker of ovarian reserve available. Unlike other hormones, AMH can be measured on any day of the cycle. Higher values indicate greater reserve; lower values suggest reduced reserve.

Age-stratified AMH reference ranges vary by laboratory, but as a rough guide:

• Optimal (25–35 years): 14–48 pmol/L (2–6.8 ng/mL)
• Satisfactory: 7–14 pmol/L (1–2 ng/mL)
• Low: 2–6.99 pmol/L (0.3–0.99 ng/mL)
• Very low: <2 pmol/L (<0.3 ng/mL)

An important caveat: AMH predicts quantity of eggs, not quality. A woman with low AMH can still conceive naturally or with treatment — it simply means the window of fertility is narrower and time is of the essence.

Antral Follicle Count (AFC): Performed by transvaginal ultrasound, typically on days 2–5 of the cycle, AFC counts the number of small resting follicles (2–10 mm) in both ovaries. Normal AFC is typically 10–20 total; AFC <7 suggests diminished ovarian reserve. AFC and AMH are closely correlated and are complementary tests.

Day 2–3 FSH and Oestradiol: Elevated FSH (>10–12 IU/L depending on laboratory) on day 2–3 of the cycle indicates the pituitary is working harder to stimulate a diminished follicle pool. An elevated oestradiol on the same day can artificially suppress FSH, masking diminished reserve — so both must be interpreted together.

Ovulation Assessment

Mid-Luteal Progesterone (Day 21 Progesterone): A serum progesterone level drawn 7 days before expected period (day 21 in a 28-day cycle, or adjusted accordingly) confirms ovulation. A level >16–30 nmol/L (5–10 ng/mL, with exact thresholds varying by laboratory) indicates ovulation has occurred. Levels >30 nmol/L suggest adequately luteinised ovulation.

Cycle Tracking with LH Monitoring: Serial LH testing using digital or quantitative ovulation predictor kits, ideally combined with BBT charting and oestrogen monitoring, provides detailed information about ovulatory timing.

Ultrasound Tracking: Serial transvaginal ultrasounds through a cycle can confirm follicular growth, predict ovulation, and confirm ovulation has occurred (by the disappearance of the follicle and the appearance of free fluid).

Uterine and Tubal Assessment

Hysterosalpingography (HSG): An X-ray procedure in which radiopaque dye is injected through the cervix into the uterus and fallopian tubes. HSG assesses uterine cavity shape and tubal patency (whether the tubes are open). It is typically performed on days 5–12 of the cycle. Normal HSG shows dye flowing freely through both tubes and spilling into the peritoneal cavity.

HyCoSy (Hysterosalpingo-Contrast Sonography): An ultrasound-based alternative to HSG using foam or bubbles, increasingly used in Europe. It carries similar accuracy to HSG for tubal patency assessment with less radiation exposure and comparable patient comfort.

Saline Infusion Sonohysterography (SIS): An ultrasound procedure in which saline is injected into the uterine cavity, distending it and allowing visualisation of the endometrial lining. It is superior to regular ultrasound for identifying intrauterine abnormalities including polyps, submucosal fibroids, and uterine septa.

Hysteroscopy: Direct endoscopic visualisation of the uterine cavity. The gold standard for assessing the uterine cavity and treating abnormalities found on imaging.

Laparoscopy: A surgical procedure that provides direct visualisation of the pelvis, allowing assessment of the ovaries, fallopian tubes, and surrounding structures. Essential for diagnosing endometriosis and assessing tubal anatomy in more detail than HSG allows.

Hormonal Assessment

A comprehensive hormonal panel should include:

• TSH (Thyroid Stimulating Hormone): Thyroid dysfunction is a common cause of cycle irregularity and infertility
• Prolactin: Elevated prolactin suppresses LH and FSH, causing anovulation
• LH and FSH (day 2–3): High LH:FSH ratio (>2:1) is characteristic of PCOS
• Oestradiol (E2, day 2–3): See above re interpretation with FSH
• Testosterone (total and free) and DHEAS: Elevated in androgen excess conditions including PCOS
• SHBG: Sex hormone-binding globulin; low levels increase free androgen activity

Male Fertility Testing

Semen Analysis

Semen analysis remains the cornerstone of male fertility assessment. The 2021 WHO reference values are:

• Volume: ≥1.4 mL
• Total sperm number: ≥39 million per ejaculate
• Sperm concentration: ≥16 million/mL
• Progressive motility: ≥30%
• Total motility: ≥42%
• Normal morphology (Kruger): ≥4%

Importantly, at least two semen analyses should be performed, separated by 2–4 weeks, as sperm parameters show significant intraindividual variability.

Sperm DNA Fragmentation Testing

As discussed, sperm DNA fragmentation is not measured by standard semen analysis. Testing methods include the TUNEL assay, sperm chromatin structure assay (SCSA), and COMET assay. A DFI above 25–30% is clinically significant and warrants intervention (lifestyle changes, antioxidant therapy, and in some cases, testicular sperm extraction for IVF/ICSI).

Male Hormonal Testing

Men with abnormal semen analyses should have: testosterone (total and free), FSH, LH, prolactin, and TSH. Hormone testing helps distinguish between primary testicular failure (elevated FSH), secondary hypogonadism (low LH/FSH with low testosterone), and obstructive causes (normal hormones).

Genetic Testing in Male Infertility

Men with severe oligospermia (<5 million/mL) or azoospermia should be offered:

• Karyotype: Klinefelter syndrome (47,XXY) is the most common sex chromosome abnormality and a significant cause of azoospermia
• Y-chromosome microdeletion analysis: Deletions in the AZF regions of the Y chromosome cause spermatogenic failure in 10–15% of azoospermic men
• CFTR mutation testing: Men with congenital bilateral absence of the vas deferens (CBAVD) carry CFTR mutations; partner testing is important for pregnancy counselling

Interpreting Results: What Normal and Abnormal Actually Mean

Fertility test results exist on a spectrum rather than as simple pass/fail. A "normal" result reduces the probability of that specific factor being a major contributor to infertility — it doesn't guarantee fertility. An "abnormal" result points towards a likely contributor but rarely tells the complete story.

Key principles for interpretation:

• Results must be interpreted in clinical context, not in isolation
• A single abnormal result rarely constitutes a diagnosis; retesting and triangulating with other investigations is standard
• Reference ranges are population-based and reflect the lower limits of men/women who fathered children or conceived — not absolute fertility thresholds
• Age is always an important contextual variable

Home Fertility Testing: What's Available and How Reliable Is It?

A growing range of home fertility tests offers accessible first-line assessment:

AMH Home Tests: Finger-prick blood tests measuring AMH at home have become popular. They correlate reasonably well with clinic-measured AMH, though absolute accuracy is somewhat lower. They are a useful screening tool but should be confirmed by a clinic if results are borderline or unexpected.

At-Home Semen Analysis: Devices measuring sperm concentration and total motile count at home are increasingly available. They provide useful screening information, though morphology and DNA fragmentation cannot be assessed at home.

Cycle Tracking Apps with Hormone Monitoring: Hormone-monitoring devices (such as those measuring urinary oestrogen and LH) combined with app algorithms offer reasonably accurate ovulation prediction and can give couples insight into cycle characteristics — including potential anovulatory cycles.

Frequently Asked Questions About Fertility Testing

Q: What's the single most important fertility test for a woman?
A: AMH and AFC together give the most comprehensive picture of ovarian reserve. For overall fertility assessment, a full panel (AMH, AFC, Day 2-3 FSH/LH/E2, progesterone confirmation of ovulation, and uterine assessment) is ideal.

Q: Can I do fertility testing even if I'm not trying to conceive yet?
A: Absolutely. Fertility preservation planning — knowing your ovarian reserve, identifying any potential issues early — is increasingly part of proactive reproductive health management. Testing at 25–30 gives you valuable baseline data and time to act if reserves are lower than expected.

Q: Does normal fertility testing mean I will definitely get pregnant?
A: No. Normal tests reduce the likelihood of identified causes but don't guarantee pregnancy. 10–30% of infertile couples have unexplained infertility — normal tests but difficulty conceiving.

Q: How long does a full fertility workup take?
A: Blood tests and semen analysis can be done within days. Ultrasound (AFC) and timed tests like progesterone are cycle-dependent. A full workup including HSG typically takes 4–8 weeks across one or two menstrual cycles.

Q: Is fertility testing covered by European health insurance?
A: This varies significantly by country and insurer. In many EU countries, standard fertility investigations are covered or partially reimbursed when medically indicated. Proactive (non-medically-indicated) testing is typically self-pay.

Q: What if my AMH is low — does that mean I can't have a baby?
A: No. AMH predicts quantity of eggs remaining, not the ability to conceive. Women with low AMH can and do conceive — naturally and through treatment. Low AMH does mean time is of the essence and that IVF may have fewer eggs to work with, but it is not a diagnosis of infertility.

Q: Should both partners be tested simultaneously?
A: Yes, and this is strongly recommended. Investigating only one partner first delays diagnosis and appropriate treatment. Male factor contributes to 40–50% of infertility cases and can often be identified quickly with semen analysis.

Q: What is the difference between fertility testing and genetic testing?
A: Fertility testing assesses reproductive function (egg reserve, sperm quality, structural factors). Genetic testing for fertility purposes includes carrier screening (identifying whether you carry genes for inherited conditions that could affect offspring), chromosomal analysis, and preimplantation genetic testing (PGT-A) in IVF to screen embryos. Both have a role in reproductive healthcare but serve different purposes.